The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Influenza neuraminidase: A druggable target for natural products
Abstract
The imminent threat of influenza pandemics and repeatedly reported emergence of new drug-resistant influenza virus strains demonstrate the urgent need for developing innovative and effective antiviral agents for prevention and treatment. At present, influenza neuraminidase (NA), a key enzyme in viral replication, spread, and pathogenesis, is considered to be one of the most promising targets for combating influenza. Despite the substantial medical potential of NA inhibitors (NAIs), only three of these drugs are currently on the market (zanamivir, oseltamivir, and peramivir). Moreover, sudden changes in NAI susceptibility revealed the urgent need in the discovery/identification of novel inhibitors. Nature offers an abundance of biosynthesized compounds comprising chemical scaffolds of high diversity, which present an infinite pool of chemical entities for target-oriented drug discovery in the battle against this highly contagious pathogen. This review illuminates the increasing research efforts of the past decade (2000-2011), focusing on the structure, function and druggability of influenza NA, as well as its inhibition by natural products. Following a critical discussion of publications describing some 150 secondary plant metabolites tested for their inhibitory potential against influenza NA, the impact of three different strategies to identify and develop novel NAIs is presented: (i) bioactivity screening of herbal extracts, (ii) exploitation of empirical knowledge, and (iii) computational approaches. This work addresses the latest developments in theoretical and experimental research on properties of NA that are and will be driving anti-influenza drug development now and in the near future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rational design of potent sialidase-based inhibitors of influenza virus replication
von Itzstein, M., Wu, W.-Y., Kok, G. B., Pegg, M. S., Dyason, J. C., Jin, B., Van Phan, T., Smythe, M. L., White, H. F., Oliver, S. W., et al. (1993) · Nature · doi:10.1038/363418a0 · Cited by 1,862
1918 Influenza: the Mother of All Pandemics
Taubenberger, J. K., & Morens, D. M. (2006) · Emerging Infectious Diseases · doi:10.3201/eid1201.050979 · Cited by 1,686
1918 Influenza: the Mother of All Pandemics
Taubenberger, J. K., & Morens, D. M. (2006) · Emerging Infectious Diseases · doi:10.3201/eid1209.05-0979 · Cited by 1,590
Characterization of the reconstructed 1918 Spanish influenza pandemic virus
Tumpey, T. M., Basler, C. F., Aguilar, P. V., Zeng, H., Solórzano, A., Swayne, D. E., Cox, N. J., Katz, J. M., Taubenberger, J. K., Palese, P., et al. (2005) · Science · doi:10.1126/science.1119392 · Cited by 1,327
Matrosovich, M. N., Matrosovich, T. Y., Gray, T., Roberts, N. A., & Klenk, H.-D. (2004) · Journal of Virology · doi:10.1128/jvi.78.22.12665-12667.2004 · Cited by 606
Bonten, E., van der Spoel, A., Fornerod, M., Grosveld, G., & d'Azzo, A. (1996) · Genes & Development · doi:10.1101/gad.10.24.3156 · Cited by 313
Inhibition of neuraminidase activity by derivatives of 2-deoxy-2,3-dehydro-N-acetylneuraminic acid
Meindl, P., Bodo, G., Palese, P., Schulman, J., & Tuppy, H. (1974) · Virology · doi:10.1016/0042-6822(74)90080-4 · Cited by 287
Crennell, S., Garman, E., Laver, G., Vimr, E., & Taylor, G. (1994) · Structure · doi:10.1016/s0969-2126(00)00053-8 · Cited by 205
Crystal Structure of the Human Cytosolic Sialidase Neu2
Chavas, L. M. G., Tringali, C., Fusi, P., Venerando, B., Tettamanti, G., Kato, R., Monti, E., & Wakatsuki, S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m411506200 · Cited by 176
Complexity in Influenza Virus Targeted Drug Design: Interaction with Human Sialidases
Chavas, L. M. G., Kato, R., Suzuki, N., von Itzstein, M., Mann, M. C., Thomson, R. J., Dyason, J. C., McKimm-Breschkin, J., Fusi, P., Tringali, C., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100078r · Cited by 68
Cited by
Natural products as sources of new drugs over the 30 years from 1981 to 2010
Newman, D. J., & Cragg, G. M. (2012) · Journal of Natural Products · doi:10.1021/np200906s · Cited by 4,687
Antiviral Natural Products and Herbal Medicines
Lin, L.-T., Hsu, W.-C., & Lin, C.-C. (2014) · Journal of Traditional and Complementary Medicine · doi:10.4103/2225-4110.124335 · Cited by 529
Quercetin as an Antiviral Agent Inhibits Influenza A Virus (IAV) Entry
Wu, W., Li, R., Li, X., He, J., Jiang, S., Liu, S., & Yang, J. (2015) · Viruses · doi:10.3390/v8010006 · Cited by 425
Antiviral Cyanometabolites—A Review
Mazur-Marzec, H., Cegłowska, M., Konkel, R., & Pyrć, K. (2021) · Biomolecules · doi:10.3390/biom11030474 · Cited by 64
Inhibition of sialidase activity as a therapeutic approach
Glanz, V. Y., Myasoedova, V. A., Grechko, A. V., & Orekhov, A. N. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s176220 · Cited by 59
Metadata
- Authors
- Grienke, U., Schmidtke, M., von Grafenstein, S., Kirchmair, J., Liedl, K. R., & Rollinger, J. M.
- Venue
- Nat. Prod. Rep.
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2012
- Volume
- 29
- Issue
- 1
- Pages
- 11-36
- ISSN
- 0265-0568 (ISSN-L)
- 1460-4752
- OpenAlex
- W2120106151
- Cited by
- 158
- References
- 10
- FWCI
- 8.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Influenza neuraminidase: A druggable target for natural products. https://app.cochat.ai/papers/10.1039/c1np00053e
- The paper
- Grienke, U., Schmidtke, M., von Grafenstein, S., Kirchmair, J., Liedl, K. R., & Rollinger, J. M. (2012). Influenza neuraminidase: A druggable target for natural products. Nat. Prod. Rep. https://doi.org/10.1039/c1np00053e
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.